Novo Nordisk’s Ozempic and Wegovy continue to outpace Eli Lilly’s Mounjaro and Zepbound, even though the latter are ...

Nordic firms have outperformed those from the rest of Europe over the past decade. In all four countries, listed ...

With a Goldilocks economy and a bull market charging into a second year, 2024 shaped up to be a good year for investors. Now, ...